Premium
Decreased risk for metabolic syndrome through reduction in uric acid production using Allopurinol
Author(s) -
Davis Meg,
Shelmadine Brian,
Bowden Rodney G,
Wilson Ronald L,
Gentile Mindy,
Willoughby Darryn
Publication year - 2007
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.21.6.lb77-a
Subject(s) - allopurinol , uric acid , medicine , metabolic syndrome , hyperuricemia , cholesterol , gout , endocrinology , lipoprotein , high density lipoprotein , hemodialysis , triglyceride , gastroenterology , obesity
Allopurinol was administered to End‐Stage Renal Disease patients presenting with symptoms of gout and risk factors of metabolic syndrome. The purpose of this pilot study was to explore whether lowering uric acid levels using Allopurinol would improve the lipoprotein markers of metabolic syndrome in patients. Previous study authors have reported significant changes in risk markers for Metabolic Syndrome in animal models. Method: Eight men and four women undergoing chronic hemodialysis were recruited through the treating physician to participate in this pilot study. All patients were prescribed Allopurinol (300 mg/bid) for 3 months. Pretest and posttest data was obtained on low‐density lipoprotein (LDL) cholesterol, LDL particle number, LDL particle size, high density lipoprotein (HDL) cholesterol, large HDL particle number, total cholesterol, triglycerides, and uric acid. Results: ANOVA revealed significant changes occurred in serum uric acid level (p = 0.001). Interesting trends were observed in LDL, HDL, LDL particle size, triglyceride and total cholesterol that warrant further investigation. Conclusion: Observed trends in some markers of the metabolic syndrome provide support for continued exploration of the use of Allopurinol in ESRD patients.